Sunday, December 31, 2017 12:04:16 PM
While one could argue that the strategy is the same, the execution of that strategy is very different under Li versus Steipp. First, by saying "some manufacturing contracts outside of CE" I didn't mean low lying fruit like an overpriced pocket knife. From all indications, Li is pursuing contracts in medical and automotive. Second, LQMT has more BMG machines, more BMG formulations, and different types of BMG formulations under Li than under Steipp - i.e. Li is executing his strategy different than Steipp did. Third, under Li LQMT is offering manufacturing capabilities outside of BMG. In short, Li is not going down the same road that Steipp did.
Recent LQMT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2026 08:37:19 PM
- Liquidmetal Technologies Inc. to Present at the LD Micro Main Event XIX • Newsfile • 10/06/2025 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 08:00:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2025 08:02:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2025 08:02:37 PM
